Background. Intravenous immunoglobulin (IVIG) is a purified pool of human antibodies from thousands of donors that is used to prevent or treat primary immune deficiency, several infectious diseases, and autoimmune diseases. The antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against heterologous influenza strains may be present in IVIG preparations.
The emergence of a swine-origin H1N1 influenza (A(H1N1)pdm09) virus in 2009 resulted in 100,000 to 400,000 deaths worldwide [1] [2] [3] [4] [5] . In most cases the vaccine was available too late to reduce the peak of the pandemic [6] [7] [8] [9] . With the threats of avian A(H7N9) and A(H5N1) pandemics looming, there is a need for new influenza therapies.
Antibodies with both neutralizing and nonneutralizing functions develop following natural influenza virus infection. Influenza hemagglutinin (HA)-specific antibodies neutralize by binding to epitopes surrounding the receptor-binding pocket and prevent sialic acid receptor binding, entry, or viral fusion. Nonneutralizing antibodies to influenza virus have the potential to mediate other effector functions including complement fixation [1, 2] , phagocytosis [10, 11] , and antibodydependent cellular cytotoxicity (ADCC) [12] [13] [14] [15] [16] . ADCC mediating antibodies can bind to regions of influenza virus and mediate their activity through ligation of CD16 (FcγRIIIa) on effector cells such as natural killer (NK) cells [17, 18] . Recent mouse studies show ADCC function is critical for protection against lethal influenza virus challenge [19, 20] .
Intravenous immunoglobulin (IVIG) is a pooled source of purified human immunoglobulin G (IgG) antibodies extracted from donor serum. IVIG is used to treat and prevent a range of infectious and autoimmune diseases [21] [22] [23] [24] . Previous influenza virus infections of donors may result in IVIG preparations containing cross-reactive ADCC mediating antibodies. IVIG preparations, pooled from thousands of blood donors, provide an opportunity to study influenza antibodies at a population level. Recent studies suggest that IVIG preparations made prior to 2009 contain some level of A(H1N1)pdm09-specific neutralizing antibodies [25] [26] [27] . The administration of post-immune IVIG to patients suffering from severe A(H1N1)pdm09 influenza has therapeutic benefit if administered within 5 days of symptom onset [28] . However, the ability of human IVIG preparations to mediate cross-reactive ADCC against diverse influenza viruses is unknown. We hypothesized that cross-reactive ADCC mediating antibodies to A(H1N1)pdm09 virus are present in IVIG preparations made prior to the 2009 pandemic.
METHODS

IVIG Samples
IVIG preparations from 2004 to 2010 (Table 1 , Sandoglobulin, CSL Behring, Australia) were prepared by cold ethanol fractionation process and are approximately 96% pure IgG. IVIG donors were human immunodeficiency virus (HIV)-antibody negative. The stock preparations are prepared to a concentration of 60-100 mg/mL. All IVIG samples were diluted to 10 mg/mL and heat-inactivated (56°C for 60 minutes).
Additional Human Sera Samples
Sixty-two serum samples collected from healthy human subjects were kindly provided by the WHO Collaborating Centre on Influenza and the University of Melbourne. Samples were collected between 2012 and 2013 from individuals aged 20-89 (median 51, ages 21-30 n = 8, 31-40 n = 11, 41-50 n = 12, 51-60 n = 10, 61-70 n = 10, 71-80 n = 7, 81-90 n = 4). The Alfred Hospital and University of Melbourne ethics committees approved the use of human donor blood and plasma samples. Human influenza-seronegative (MBL) and seronegative pigtail macaque sera (naive sera) were used as additional negative controls as previously described [29] .
Influenza Virus Antigens and HI Assay
Mammalian-cell expressed recombinant HA proteins were purchased from Sinobiologicals (Shanghai, China). Neuraminidase was purified by negative immunoaffinity based on a modified method as described [30] . HA2 was purified by solubilizing β propriolactone inactivated whole virus with buffered 4% Triton-X100 (2 hours, 37°C). Virus cores were removed using ultracentrifugation and residual detergent removed using Boibeads (Biorad). Neuaminidase protein was removed using a specific anti-N1 monoclonal antibody and affinity chromatography. Purified HA was reduced (10 mM DTT 30′ RT), and this reduced protein loaded on to a 10% bis Tris NuPAGE gel (Invitrogen Life Technology). Identified HA2 protein was excised from the gel and eluted by diffusion. Purity was confirmed by Western blotting and enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies reactive to HA2 (n = 3) and not reactive to H1, matrix, NP, and N1 antibodies. Hemagglutination inhibition (HI) assays were performed as previously described [31] .
ADCC NK Cell Activation Assays
We described ADCC assays that measure antibody-mediated NK cell activation [16] . Briefly 96-well ELISA plates (Nunc, Rochester, NY) were coated overnight at 4°C with purified influenza protein (400 ng/well) in phosphate-buffered saline (PBS). Wells were washed and incubated with heat-inactivated IVIG in fetal calf serum (FCS;starting concentration 10 mg/mL IgG) for 2 hours at 37°C. Plates were washed, and then 10 6 freshly isolated human peripheral blood mononuclear cells (PBMCs) from a healthy donor were added to each well. Brefeldin A (5 µg/mL, Sigma, St. Louis, MO) and Monensin (5 µg/mL, BD Bioscience, San Jose, CA) were added and incubated for 5 hours at 37°C. Cells were then labeled with anti-CD3-PerCP (clone SP34-2), anti-CD14-PE-Cy7 (clone M5E2) anti-CD56-APC (clone B159) and anti-CD107a-APC-H7 (clone H4A3, all from BD Bioscience) for 30 minutes. Cells were fixed, permeabilized, and incubated for 1 hour with anti-IFN-γ-AlexaFluor700 (clone B27). Cells fixed and acquired on an LSRII flow cytometer. Mammalian cell produced HIV-1 AD8 gp140 protein was included as a negative control antigen [29] . To reduce variability across assays, the same healthy blood donor was used as a source of fresh NK cells for all ADCC assays.
Antibody-Dependent Cellular Viral Elimination (ADCVE) Assay
We employed the recently described assay that measured antibody-mediated killing of influenza-infected respiratory epithelial cells [29] . Figures 1B, 1C , 1E, 2, and 5F were analyzed using Mann-Whitney U-tests. Data in Figure 3B and 3C were analyzed by Kruskal-Wallis tests, followed by 3 Mann-Whitney U-tests and subsequent Bonferroni correction to the α-level, whereby differences of P < .016 are considered significantly different. Figure 5C and 5D were similarly analyzed but no adjustment was necessary. Data in Figure 4A -E were analyzed using Wilcoxon signed-rank tests. Data in Figure 4F and 4G were analyzed by Friedman tests followed by Dunn post hoc tests. Data in Figure 5A and 5B were analyzed by Friedman tests followed by Wilcoxon signed-rank tests and Bonferroni corrections leading to a new α-level of 0.016.
RESULTS
HA-specific ADCC Toward A(H1N1)pdm09 Virus is Present in IVIG Prior to 2009 Pandemic
To determine the level of preexisting ADCC-mediating antibodies toward A(H1N1)pdm09 virus, we evaluated a panel of 18 IVIG samples manufactured prior to and following the 2009 H1N1 pandemic (Table 1 ). There were modest titers of HI antibodies to A(H1N1)pdm09 virus in IVIGs manufactured prior to the 2009 H1N1 pandemic (mean HI titer of 70; range, 16-256), which increased significantly in IVIGs prepared following the 2009 H1N1 pandemic (mean HI titer of 364; range, 64-1024, P < .001).
To first assess A(H1N1)pdm09 HA-specific ADCC antibodies in IVIG prior to and following the 2009 H1N1 pandemic, we performed an antibody-mediated NK cell activation assay [29] . We measured NK cell activation (intracellular interferon γ [IFN-γ] and the surface degranulation marker CD107a expression) in the presence of HA proteins from the pandemic A (H1N1)pdm09 virus strain or seasonal H1N1 influenza vaccine strains ( Figure 1A The levels of NA-specific ADCC in IVIG was reduced in comparison to HA-specific ADCC, consistent with our previous observations on NA-specific ADCC following H1N1 influenza infection [32] . Endpoint titrations of the H1N1pdm NA-specific ADCC response found low (1:10 responses observed in 6 samples, Figure 2A Figure 3B ). The 10 IVIG samples prepared following the 2009 H1N1 pandemic had a further enhanced capacity to clear A(H1N1)pdm09-infected respiratory cells (P < .001, Figure 3B ). Incubation of all 18 IVIG samples with the A (H1N1)pdm09-infected respiratory cells and PBMCs resulted in a marked increase in expression of the degranulation marker CD107a on NK cells ( Figure 3A lower panel and 3C) . Thus, ADCC mediating antibodies found in IVIG both prior to and following the 2009 H1N1 pandemic can both mediate NK cell activation and, importantly, eliminate A(H1N1)pdm09-infected respiratory cells.
IVIG Recognition of HA1 and Conserved Regions of HA2 Stem by ADCC
The broad cross-reactivity of HA-specific ADCC in IVIG suggests the recognition of conserved HA sequences. The HA0 protein can be divided into 2 regions, HA1 and HA2. The HA2 region is more conserved and a target for broadly cross-reactive neutralizing antibodies [33] [34] [35] . To determine the regions targeted by HA-specific ADCC we measured NK cell activation to whole HA compared to the HA1 protein using IVIG preparation made prior to 2009 and post-2009 at a 10 mg/mL concentration of IVIG. At 10 mg/mL IVIG, we observed no difference in NK cell activation toward whole HA0 protein or HA1 protein (either IFN-γ or CD107a expression) in the presence of IVIG preparations (P > .05, Figure 4A and 4B-IVIG samples pre-and post 2009 are shown as squares and circles, respectively, in the figure). In endpoint titration experiments, however, we observed that IVIG samples had significantly lower ADCC titers to HA1 protein (A/California/04/2009) compared to ADCC titers to HA0 protein (P < .001, Figure 4C ). 1280) a threshold of 2 times background (with IVIG but without HA/HA1 protein) was used to determine endpoint (I). All samples were corrected for background based on their response to a well containing IVIG but with no plate-bound antigen. Lines represent the median. Groups in A to E were compared using Wilcoxon signed-rank tests. Groups in F and G were compared using Friedman tests (P < .001 for both F and G) followed by Dunn post hoc tests. Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; HA, hemagglutinin; HIV, human immunodeficiency virus; IFN, interferon; IVIG, intravenous immunoglobulin; NK, natural killer.
This suggests that a proportion of the ADCC response is directed toward the HA1 proportion.
The measurement of influenza-specific antibodies toward HA2 is made difficult by the availability of HA2 protein in native conformation. The only available HA2 protein from A/California/04/ 2009 was purified from split whole virion preparations following detergent solubilization, negative immune affinity chromatography, and gel electrophoresis. The stability of HA2 protein was confirmed by enzyme immunoassay (EIA) using IVIG preparations and anti-HA2 monoclonal antibodies (n = 3, data not shown). Using this purified HA2 protein, we detected moderate antibody-mediated NK cell activation (both IFN-γ and CD107a expression) toward HA2 in IVIG preparations compared to HIV gp140 protein controls (P < .005, Figure 4D and 4E ). Groups in A to B were compared using Wilcoxon signed-rank tests. Groups were compared using Friedman tests (P < .001 for both A and B) followed by 3 Wilcoxon signed-rank tests, or Kruskal-Wallis tests (P < .001 for C and P = .0254 for D) followed by 3 Mann-Whitney U-tests. For A to C, a Bonferroni correction was applied to the post hoc tests, making P values < .016 considered significantly different. In F, groups were compared using a Mann-Whitney U-Test. Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; HA, hemagglutinin; IVIG, intravenous immunoglobulin; NK, natural killer.
ADCC Antibodies in IVIG Cross-react to Divergent Influenza Strains
Influenza virus HA glycoproteins are classified phylogenetically into group 1 (H1, H2, H5) or group 2 (H3, H4, H7) [36] . The HA proteins from A(H7N9) and A(H5N1) are of interest given their pandemic potential [37] [38] [39] . IVIG is known to contain low-level broadly cross-reactive antibodies to both group 1 and 2 influenza A strains [35, [40] [41] [42] . This may include antibodies to the HA-stem region, directed primarily to the alphahelical region between HA1-HA2 [20] . We detected IVIGmediated NK cell activation toward all HA proteins tested including H7 and H5, without observable difference in ADCC activity-comparing IVIG samples from before or after 2009 ( Figure 4F and 4G) . The median NK cell activation (% NK cells expressing IFN-γ) induced by the 18 IVIGs to H3 and H4 was significantly higher than that induced by H2, H5, and H7 proteins ( Figure 4F ) . Similarly, NK cell expression of CD107a induced by the IVIGs to H3 was significantly higher than that induced by H2, H5, and H7 ( Figure 4G ). Endpoint titration of IVIG against a H4 whole HA protein and HA1 protein suggested there was a significant difference between ADCC responses measured against whole HA protein and HA1 protein using IVIG manufactured prior to 2009 and post-2009 ( Figure 4H and 4I, P < .001).
ADCC Recognition of H7N9 HA by IVIG
The recent outbreak of H7N9 influenza in humans highlights the need for new influenza therapeutics [38, 43] . Although ADCC recognition of H7 protein in IVIG was low, even lowlevel cross-reactive ADCC may be useful in treating severe influenza virus infection. To determine the range of cross-reactivity we measured ADCC-mediated NK cell activation towards A ( Figure 5A and 5B). We detected similar ADCC responses towards HA1 and HA0 proteins from A/Anhui/01/2013, suggesting these antibodies are at least partially directed towards the HA1 portion of H7N9 HA ( Figure 5C and 5D ). To quantitate H7-specific ADCC in IVIG further we determined end-point titers toward A/Anhui/01/2013 in comparison to A(H1N1) pdm09. We found very low titers (<20) of ADCC mediating antibodies toward H7N9 HA protein in contrast to A(H1N1) pdm09 HA (median, 155; range, 80-320; Figure 5E and 5F ).
ADCC Recognition of H7N9 HA by Healthy Donors
The low level of ADCC mediating antibodies toward H7N9 HA protein suggests that either cross-reactive ADCC antibodies are found at low concentration in multiple individuals or rare donors in the population contribute significantly titers of H7N9 HA-specific ADCC. We therefore evaluated serum obtained 
DISCUSSION
Improved antiviral therapies that provide broad protection from diverse influenza virus infections are needed [3] [4] [5] [6] [7] [8] [9] . We found IVIG preparations made prior to 2009 had substantial ADCC activity to HA and NA proteins of the A(H1N1)pdm09 virus. These ADCC mediating antibodies within IVIG activated NK cells were present at moderate titers and could eliminate A (H1N1)pdm09-infected respiratory cells in vitro. Further evaluation of ADCC mediating antibodies in IVIG as an immunoprophylaxis or immunotherapy against influenza virus infection is warranted, particularly where effective vaccines or other therapies are not available.
Antibodies capable of nonneutralizing function may have a broader degree of cross-reactivity than their neutralizing counterparts [29] . We found IVIG preparations contained ADCC mediating antibodies reactive against group 1 and group 2 influenza virus HA proteins including avian H5N1 and H7N9. This is consistent with our studies showing cross-reactive ADCC antibodies in healthy subjects [20, 29] . Several broadly neutralizing antibodies against stem-regions of HA have robust ADCC function in mice [19, 36] .
Further experiments on the efficacy of ADCC mediating antibodies within IVIG in animal models of influenza are warranted. Indeed, we recently found that a human dose equivalent of Our studies indicate cross-reactive ADCC antibodies toward H5N1 and H7N9 are present within IVIG at low concentrations. This is likely due to only a small number of individual IVIG donors contributing H7N9 cross-reactive ADCC antibodies. The generation of rare subsets of cross-reactive influenzaspecific antibodies has been previously discussed in other studies [44] . The isolation of antibodies from such donors could lead to the generation of more potent antibody preparations [28] .
We recognize that there are limitations to our study that warrant future investigations. (1) Our data do not show that influenza ADCC antibodies in IVIG are protective in vivo. Recent studies with broadly neutralizing stem-antibodies suggest that ADCC activity is essential for in vivo potency in mice [19] . Studies on the direct role of cross-reactive ADCC mediating antibodies in IVIG for in vivo protection against emerging influenza strains are necessary. (2) The poorer conformational stability of HA1 and HA2 proteins compared to HA0 proteins used in this study may underestimate endpoint ADCC titers to these proteins. While we show as a proof-of-principle that HA2 region can be a target of ADCC mediating antibodies, further measures of the relative contribution of ADCC antibodies to each region and the mapping of specific ADCC epitopes is warranted. (3) We show IVIG contains ADCC antibodies that can kill A (H1N1)pdm09-infected cells. However, further investigation of the ability of ADCC antibodies in IVIG to kill cells infected with a wider range of IAVs is needed. (4) Although we identified 1 individual subject out of 62 screened that had H7-specific ADCC, this does not definitively show that these rare individuals are contributing the H7-specific ADCC within IVIG. Analyses of sera from larger numbers of subjects are warranted.
In summary, IVIG preparations made prior to the 2009-H1N1 pandemic contain cross-reactive ADCC mediating antibodies towards A(H1N1)pdm09 HA and NA proteins. Further, there is cross-reactive ADCC mediating antibodies against avian origin influenza strains H5N1 and H7N9 within IVIG. These studies suggest the possible utility of IVIG as a therapy during influenza pandemics.
Notes
